PROGNOSTIC IMPACT OF THE MAXIMAL EVALUABLE LESION SIZE IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH NIVOLUMAB PLUS IPILIMUMAB COMBINATION THERAPY

被引：0
|
作者：
Mita, Yoshie
Teishima, Jun
Hara, Takuto
Bando, Yukari
Suzuki, Kotaro
Terakawa, Tomoaki
Chiba, Koji
Miyake, Hideaki
机构：
来源：
JOURNAL OF UROLOGY | 2025年 / 213卷 / 5S期
关键词：
D O I：
10.1097/01.JU.0001110068.14710.ff.17
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP28-17
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Prognostic Impact of the Maximal Evaluable Lesion Size in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab Combination Therapy
    Mita, Yoshie
    Teishima, Jun
    Hara, Takuto
    Ueki, Hideto
    Wakita, Naoto
    Okamura, Yasuyoshi
    Suzuki, Kotaro
    Bando, Yukari
    Terakawa, Tomoaki
    Chiba, Koji
    Miyake, Hideaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2025,
  • [2] Hypopituitarism in patients with metastatic renal cell carcinoma treated with ipilimumab and nivolumab combination therapy
    Takagi, Toshio
    Yoshida, Kazuhiko
    Kondo, Tsunenori
    Fukuda, Hironori
    Ishihara, Hiroki
    Kobayashi, Hirohito
    Iizuka, Junpei
    Ishida, Hideki
    Tanabe, Kazunari
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (12) : 1744 - 1750
  • [3] Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma
    Teishima, Jun
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (09) : 752 - 753
  • [4] Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma
    Yamashita, Shimpei
    Hamamoto, Shuzo
    Furukawa, Junya
    Fujita, Kazutoshi
    Takahashi, Masayuki
    Miyake, Makito
    Ito, Noriyuki
    Iwamoto, Hideto
    Kohjimoto, Yasuo
    Hara, Isao
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [5] Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma
    Numakura, Kazuyuki
    Sekine, Yuya
    Hatakeyama, Shingo
    Muto, Yumina
    Sobu, Ryuta
    Kobayashi, Mizuki
    Sasagawa, Hajime
    Kashima, Soki
    Yamamto, Ryohei
    Nara, Taketoshi
    Akashi, Hideo
    Tabata, Ryuji
    Sato, Satoshi
    Saito, Mitsuru
    Narita, Shintaro
    Ohyama, Chikara
    Habuchi, Tomonori
    CANCER MEDICINE, 2023, 12 (16): : 16837 - 16845
  • [6] Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Ikeda, Takashi
    Ishihara, Hiroki
    Nemoto, Yuki
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Takagi, Toshio
    Iizuka, Junpei
    Hashimoto, Yasunobu
    Ishida, Hideki
    Kondo, Tsunenori
    Tanabe, Kazunari
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (10) : 735.e9 - 735.e16
  • [7] Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma
    Kobari, Yuki
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Kondo, Tsunenori
    Ishida, Hideki
    Tanabe, Kazunari
    Takagi, Toshio
    IN VIVO, 2021, 35 (06): : 3585 - 3589
  • [8] Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Yamashita, Shimpei
    Hamamoto, Shuzo
    Furukawa, Junya
    Fujita, Kazutoshi
    Takahashi, Masayuki
    Miyake, Makito
    Ito, Noriyuki
    Iwamoto, Hideto
    Kohjimoto, Yasuo
    Hara, Isao
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (06) : 722 - 729
  • [9] Pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component by nivolumab plus ipilimumab combination therapy
    Takehiro Sejima
    Toshihiko Masago
    Manabu Yoshida
    Takeshi Nishi
    Yasunari Kawabata
    Yoshitsugu Tajima
    Tetsuya Yumioka
    Masashi Honda
    Atsushi Takenaka
    International Cancer Conference Journal, 2021, 10 : 285 - 289
  • [10] Pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component by nivolumab plus ipilimumab combination therapy
    Sejima, Takehiro
    Masago, Toshihiko
    Yoshida, Manabu
    Nishi, Takeshi
    Kawabata, Yasunari
    Tajima, Yoshitsugu
    Yumioka, Tetsuya
    Honda, Masashi
    Takenaka, Atsushi
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2021, 10 (04) : 285 - 289
12345